CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges
Clustered regularly interspaced short palindromic repeats (CRISPR) is described as RNA mediated adaptive immune system defense, which is naturally found in bacteria and archaea. CRISPR-Cas9 has shown great promise for cancer treatment in cancer immunotherapy, manipulation of cancer genome and epigen...
Gespeichert in:
Veröffentlicht in: | Briefings in functional genomics 2020-05, Vol.19 (3), p.209-214 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 214 |
---|---|
container_issue | 3 |
container_start_page | 209 |
container_title | Briefings in functional genomics |
container_volume | 19 |
creator | Cheng, Xing Fan, Shaoyi Wen, Chengcai Du, Xianfa |
description | Clustered regularly interspaced short palindromic repeats (CRISPR) is described as RNA mediated adaptive immune system defense, which is naturally found in bacteria and archaea. CRISPR-Cas9 has shown great promise for cancer treatment in cancer immunotherapy, manipulation of cancer genome and epigenome and elimination or inactivation of carcinogenic viral infections. However, many challenges remain to be addressed to increase its efficacy, including off-target effects, editing efficiency, fitness of edited cells, immune response and delivery methods. Here, we explain CRISPR-Cas classification and its general function mechanism for gene editing. Then, we summarize these preclinical CRISPR-Cas9-based therapeutic strategies against cancer. Moreover, the challenges and improvements of CRISPR-Cas9 clinical applications will be discussed. |
doi_str_mv | 10.1093/bfgp/elaa001 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_bfgp_elaa001</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32052006</sourcerecordid><originalsourceid>FETCH-LOGICAL-c329t-28c1c100fb20d4b16da271c62fa13420a06515a7b22806259e516fe298cbd8673</originalsourceid><addsrcrecordid>eNpNkLFOwzAURS0EolXpxoz8AQ19z06chA1FFCpVAhWYoxfHboNcJ4rD0L-nVQviLvcOR3c4jN0i3CPkcl7ZTTc3jggAL9hYQIyRUEl6-W-P2DSELzhEYhwjXLORFJAIADVm62K9fH9bzwsKObdtzzV5bXo-9IaGnfHDAx-M3vrWtZv9jGvX-EaT49R17jCGpvWBk6-53pJzxm9MuGFXllww03NP2Ofi6aN4iVavz8vicRVpKfIhEplGjQC2ElDHFaqaRIpaCUsoYwEEKsGE0kqIDJRIcpOgskbkma7qTKVywmanX923IfTGll3f7Kjflwjl0U55tFOe7RzwuxPefVc7U__Bvy7kD5DzYF4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Cheng, Xing ; Fan, Shaoyi ; Wen, Chengcai ; Du, Xianfa</creator><creatorcontrib>Cheng, Xing ; Fan, Shaoyi ; Wen, Chengcai ; Du, Xianfa</creatorcontrib><description>Clustered regularly interspaced short palindromic repeats (CRISPR) is described as RNA mediated adaptive immune system defense, which is naturally found in bacteria and archaea. CRISPR-Cas9 has shown great promise for cancer treatment in cancer immunotherapy, manipulation of cancer genome and epigenome and elimination or inactivation of carcinogenic viral infections. However, many challenges remain to be addressed to increase its efficacy, including off-target effects, editing efficiency, fitness of edited cells, immune response and delivery methods. Here, we explain CRISPR-Cas classification and its general function mechanism for gene editing. Then, we summarize these preclinical CRISPR-Cas9-based therapeutic strategies against cancer. Moreover, the challenges and improvements of CRISPR-Cas9 clinical applications will be discussed.</description><identifier>ISSN: 2041-2657</identifier><identifier>EISSN: 2041-2657</identifier><identifier>DOI: 10.1093/bfgp/elaa001</identifier><identifier>PMID: 32052006</identifier><language>eng</language><publisher>England</publisher><ispartof>Briefings in functional genomics, 2020-05, Vol.19 (3), p.209-214</ispartof><rights>The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c329t-28c1c100fb20d4b16da271c62fa13420a06515a7b22806259e516fe298cbd8673</citedby><cites>FETCH-LOGICAL-c329t-28c1c100fb20d4b16da271c62fa13420a06515a7b22806259e516fe298cbd8673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32052006$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cheng, Xing</creatorcontrib><creatorcontrib>Fan, Shaoyi</creatorcontrib><creatorcontrib>Wen, Chengcai</creatorcontrib><creatorcontrib>Du, Xianfa</creatorcontrib><title>CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges</title><title>Briefings in functional genomics</title><addtitle>Brief Funct Genomics</addtitle><description>Clustered regularly interspaced short palindromic repeats (CRISPR) is described as RNA mediated adaptive immune system defense, which is naturally found in bacteria and archaea. CRISPR-Cas9 has shown great promise for cancer treatment in cancer immunotherapy, manipulation of cancer genome and epigenome and elimination or inactivation of carcinogenic viral infections. However, many challenges remain to be addressed to increase its efficacy, including off-target effects, editing efficiency, fitness of edited cells, immune response and delivery methods. Here, we explain CRISPR-Cas classification and its general function mechanism for gene editing. Then, we summarize these preclinical CRISPR-Cas9-based therapeutic strategies against cancer. Moreover, the challenges and improvements of CRISPR-Cas9 clinical applications will be discussed.</description><issn>2041-2657</issn><issn>2041-2657</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpNkLFOwzAURS0EolXpxoz8AQ19z06chA1FFCpVAhWYoxfHboNcJ4rD0L-nVQviLvcOR3c4jN0i3CPkcl7ZTTc3jggAL9hYQIyRUEl6-W-P2DSELzhEYhwjXLORFJAIADVm62K9fH9bzwsKObdtzzV5bXo-9IaGnfHDAx-M3vrWtZv9jGvX-EaT49R17jCGpvWBk6-53pJzxm9MuGFXllww03NP2Ofi6aN4iVavz8vicRVpKfIhEplGjQC2ElDHFaqaRIpaCUsoYwEEKsGE0kqIDJRIcpOgskbkma7qTKVywmanX923IfTGll3f7Kjflwjl0U55tFOe7RzwuxPefVc7U__Bvy7kD5DzYF4</recordid><startdate>20200520</startdate><enddate>20200520</enddate><creator>Cheng, Xing</creator><creator>Fan, Shaoyi</creator><creator>Wen, Chengcai</creator><creator>Du, Xianfa</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20200520</creationdate><title>CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges</title><author>Cheng, Xing ; Fan, Shaoyi ; Wen, Chengcai ; Du, Xianfa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c329t-28c1c100fb20d4b16da271c62fa13420a06515a7b22806259e516fe298cbd8673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Cheng, Xing</creatorcontrib><creatorcontrib>Fan, Shaoyi</creatorcontrib><creatorcontrib>Wen, Chengcai</creatorcontrib><creatorcontrib>Du, Xianfa</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Briefings in functional genomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cheng, Xing</au><au>Fan, Shaoyi</au><au>Wen, Chengcai</au><au>Du, Xianfa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges</atitle><jtitle>Briefings in functional genomics</jtitle><addtitle>Brief Funct Genomics</addtitle><date>2020-05-20</date><risdate>2020</risdate><volume>19</volume><issue>3</issue><spage>209</spage><epage>214</epage><pages>209-214</pages><issn>2041-2657</issn><eissn>2041-2657</eissn><abstract>Clustered regularly interspaced short palindromic repeats (CRISPR) is described as RNA mediated adaptive immune system defense, which is naturally found in bacteria and archaea. CRISPR-Cas9 has shown great promise for cancer treatment in cancer immunotherapy, manipulation of cancer genome and epigenome and elimination or inactivation of carcinogenic viral infections. However, many challenges remain to be addressed to increase its efficacy, including off-target effects, editing efficiency, fitness of edited cells, immune response and delivery methods. Here, we explain CRISPR-Cas classification and its general function mechanism for gene editing. Then, we summarize these preclinical CRISPR-Cas9-based therapeutic strategies against cancer. Moreover, the challenges and improvements of CRISPR-Cas9 clinical applications will be discussed.</abstract><cop>England</cop><pmid>32052006</pmid><doi>10.1093/bfgp/elaa001</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2041-2657 |
ispartof | Briefings in functional genomics, 2020-05, Vol.19 (3), p.209-214 |
issn | 2041-2657 2041-2657 |
language | eng |
recordid | cdi_crossref_primary_10_1093_bfgp_elaa001 |
source | EZB-FREE-00999 freely available EZB journals; PubMed Central |
title | CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T00%3A12%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CRISPR/Cas9%20for%20cancer%20treatment:%20technology,%20clinical%20applications%20and%20challenges&rft.jtitle=Briefings%20in%20functional%20genomics&rft.au=Cheng,%20Xing&rft.date=2020-05-20&rft.volume=19&rft.issue=3&rft.spage=209&rft.epage=214&rft.pages=209-214&rft.issn=2041-2657&rft.eissn=2041-2657&rft_id=info:doi/10.1093/bfgp/elaa001&rft_dat=%3Cpubmed_cross%3E32052006%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32052006&rfr_iscdi=true |